Powder: -20°C for 3 years
In solvent: -80°C for 2 years
GLPG2938 is a potent and selective antagonist of S1P2.
Description | GLPG2938 is a potent and selective antagonist of S1P2. |
In vitro | GLPG2938 significantly prevents the S1P-mediated contraction at all tested concentrations[1]. |
In vivo | In all species ,GLPG2938 shows good pharmacokinetics, with long half-life,low clearance,and good bioavailability. |
Synonyms | 1-(2-Ethoxy-6-(trifluoromethyl)pyridin-4-yl)-3-((5-methyl-6-(1-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)pyridazin-3-yl)methyl)urea |
Molecular Weight | 503.409 |
Formula | C20H19F6N7O2 |
CAS No. | 2130996-00-6 |
Powder: -20°C for 3 years
In solvent: -80°C for 2 years
DMSO: 60 mg/ml (119.19 mM)
( < 1 mg/ml refers to the product slightly soluble or insoluble )
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
GLPG2938 2130996-00-6 G蛋白偶联受体 LPL Receptor S1P Receptor GLPG 2938 Lysophospholipid Receptor fibrosis inhibit 1-(2-Ethoxy-6-(trifluoromethyl)pyridin-4-yl)-3-((5-methyl-6-(1-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)pyridazin-3-yl)methyl)urea GLPG-2938 selective pulmonary Inhibitor potent idiopathic inhibitor